Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis
DOI:10.3969/j.issn.1001-5256.2020.12.015
- VernacularTitle:直接抗病毒药物对HCV相关肝细胞癌根治性治疗后复发影响的Meta分析
- Author:
Yuwei LIU
1
;
Jinglan JIN
;
Tianyi REN
;
Xiuzhu GAO
;
Jie LI
;
Qian ZHU
;
Junqi NIU
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Research Article
- Keywords:
antiviral agents;
hepacivirus;
carcinoma, hepatocellular;
recurrence;
Meta-analysis as topic
- From:
Journal of Clinical Hepatology
2020;36(12):2714-2719
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of direct-acting antiviral (DAA) on the recurrence of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after curative treatment. MethodsPubMed, Web of Science, Cochrane Library, CNKI, CBM, Wanfang Data, and VIP were searched for the clinical studies of DAA and the recurrence of HCV-related HCC published up to April 2020. Stata 14.0 software was used to perform the meta-analysis. The Cochran Q test was used to evaluate heterogeneity between studies; the fixed effects model was used for non-heterogeneous data, and the random effects model was used for heterogeneous data. The Egger regression method or the Begg rank correlation method was used to evaluate the presence or absence of publication bias. ResultsA total of 10 articles (11 studies) were included in our study, among which 8 articles (9 studies) compared the effect of DAA versus the absence of anti-HCV therapy on the recurrence of HCC after curative treatment. There were 991 patients in DAA group and 808 patients in untreated group. The results of the meta-analysis showed that DAA reduced the recurrence rate of HCC after curative treatment in patients with HCV infection (hazard ratio ［HR］=0.42, 95% confidence interval ［CI］: 0.28?0.36, P＜0.001). Three articles compared the effect of DAA versus interferon for the treatment of hepatitis C on the recurrence of HCC after curative treatment, with 267 patients in DAA group and 212 in interferon group, and the results of the meta-analysis showed that DAA and interferon had a similar effect on the recurrence rate of HCV-related HCC (HR=0.85, 95% CI: 0.64-1.15, P=0.298). ConclusionBoth interferon and DAA can significantly reduce the recurrence risk of HCV-related HCC after curative treatment, with no significant difference between them.
